Published in Drug Week, October 27th, 2006
According to recent research published in the European Journal of Haematology, "The treatment of relapsed adult ALL is frequently unsuccessful with current chemotherapy regimens, and often there is an overexpression of MDR-related proteins. Liposomal encapsulation makes daunorubicin (DNR) less sensitive to the efflux effect of P-glycoprotein (PGP), and in vitro data indicate that DNX (Daunoxome) is more toxic than DNR against ALL cell lines."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.